Mckesson Corp (MCK)
Valor JustoFundamental
79
Preço
$853.81
Capitalização de Mercado
$99.84B
Parte 1 · Quanto vale a empresa
Visão Geral
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
McKesson's 10-K names Cencora as one of its two largest competitors: both are national full-line wholesalers distributing branded, generic and specialty drugs to the same U.S. pharmacy chains, health systems and physician practices.
The other of the two competitors McKesson names by name: Cardinal Health bids for the same U.S. drug-distribution contracts and also sells medical-surgical supplies to the same hospitals and surgery centers.
Henry Schein's own 10-K names McKesson as one of its two primary national competitors in the medical market, where both supply consumables and equipment to office-based physicians and dental practices.
Privately held national distributor of medical-surgical supplies, competing head-on with McKesson Medical-Surgical for hospital, surgery-centre and physician-office supply contracts.
Distributor of medical-surgical products to U.S. acute-care hospitals and health systems, bidding for the same supply-chain contracts as McKesson's Medical-Surgical Solutions segment.
Privately held regional full-line pharmaceutical wholesaler in the U.S. South, serving the independent pharmacies and regional hospital groups that McKesson also supplies.
Balanço & Liquidez
Receita
$410.98B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$4.59B
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$5.72B
Capital Próprio Total
$-2.17B
Passivo Total
$84.10B
Rácio de Liquidez
0.89
Cobertura de Juros
23.62
Dívida/EBITDA
1.80
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$911.16
Preço Atual
$853.81
Margem de Segurança
+6.3%
Intervalo de Valor Justo
$662.92 - $1159.40
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
22.90
ROE
-219.2%
Rácio P/B
-
P/FCF
15.52
Margem Bruta
3.6%
ROIC
28.5%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
28.5%
WACC
7.3%
ROIC − WACC
+21.2 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (19)
- EPS shows upward trend
- EPS CAGR 14.57%
- Price CAGR 20.17%
- ROIC 28.5%
- P/FCF 15.52
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 39.4%
- Revenue Growth 5Y 11.1%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 2.9%
- Earnings Quality (OCF/NI) 1.49
- Share Dilution -3.1%
- Net Margin Trend 1.1% vs 0.8%
- Piotroski F-Score 7/9
Reprovado (4)
- Gross Margin 3.6%
- Operating Margin 1.6%
- Low reliance on intangibles
- DCF valuation (Overvalued)
Indisponível (5)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Chairman | 58 |
| Ms. Michele Lau J.D. | Executive VP & Chief Legal Officer | 49 |
| Ms. LeAnn B. Smith | Executive VP & Chief Human Resources Officer | 50 |
| Mr. Kenny K. Cheung | Executive VP & CFO | 43 |
| Mr. Napoleon B. Rutledge Jr. | Senior VP, Controller & Chief Accounting Officer | 52 |
| Paula Adkison | Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance | - |
| Mr. Francisco J. Fraga | Executive VP, Chief Information Officer & CTO | 52 |
| Ms. Jeni Dominguez | Head of Investor Relations | - |
| Mr. Kirk Kaminsky | Executive VP & Group President of North American Pharmaceutical Services | - |
| Mr. Stanton J. McComb | President of Medical-Surgical | - |
Risco de Auditoria
9
Risco do Conselho
6
Risco de Remuneração
1
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-05-08
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-05
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-28
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for MCK, sourced from Markets Gazette.
- 6/3/2026NEUTRALMcKesson Unit Prices $2.25 Billion Leveraged Loan Ahead of IPO
McKesson Corp.'s medical-surgical unit has priced a $2.25 billion leveraged loan. This move precedes the unit's anticipated initial public offering (IPO). While the loan issuance itself is a financing activity, its direct impact on McKesson's stock price is neutral at this stage. The successful pricing indicates market appetite for the unit's debt, which could be a positive precursor to the IPO, but the primary focus remains on the upcoming equity offering rather than the debt itself for immediate trading signals.
- 4/8/2026POSITIVEHere's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
An investment of $100 in McKesson Corporation (MCK) twenty years ago would have grown to approximately $1,640 today, representing a significant 16.4x return. This performance indicates a strong compound annual growth rate (CAGR) over the past two decades, outperforming many market benchmarks. The sustained growth suggests effective business strategy, operational efficiency, and favorable market positioning within the healthcare distribution sector. For investors, this historical data highlights McKesson's long-term value creation potential and its resilience through various economic cycles.
via Markets Gazette